ERBB2 and cancer: A study reported that only 0.0014% of Trastuzumab-coated AuNPs successfully interacted with cancer cells in tumours,118 despite Trastuzumab's well-established affinity for the HER2 cancer marker and its clinical efficacy as an FDA-approved therapy.119,120 This highlights the existence of poorly understood biological interactions that impede successful targeting.